$VRTX

Vertex Pharmaceuticals (VRTX) saw $11.6M in net ETF buying on Thursday, continuing a five-day streak. Key ETFs like XLV, QQQ, and IBB added shares. VRTX operates in biotechnology, with a market cap of $126.7B, and reported $12.7B in trailing 12-month revenue, up 13.1% YoY.

Vertex, Inc. announced its Vertex O Series Tax Engine for Oracle achieved Oracle Validated: Oracle Cloud Infrastructure Expertise. The engine is now available in Oracle Marketplace, offering centralized tax determination for Oracle Cloud customers. It processes over 150 million transactions monthly, with near push-button setup. Vertex provides indirect tax solutions globally, with software licenses and cloud subscriptions.

Vertex Pharmaceuticals (VRTX) completed its largest acquisition, Crinetics, for $10B, gaining Palsonify and Atumelnant. Palsonify, for acromegaly, and Atumelnant, for CAH and Cushing's syndrome, could generate over $5B in peak revenue. Vertex aims to diversify beyond cystic fibrosis with these and other pipeline drugs.

Moderna reported a net loss of $2.8B and revenue of $1.9B for FY 2025, with a 39.2% revenue decline due to reduced COVID-19 product demand. Vertex Pharmaceuticals reported a net income of $4B and revenue of $12.1B, with a 9.6% revenue growth. Both companies face distinct business risks and financial profiles.

Goldman Sachs raised its price target for Vertex Pharmaceuticals to $654 from $653. The company's stock is currently trading at $498.50, up 2.74% over 5 days. Vertex recently reported that its drug Alyftrek showed pancreatic function recovery in some children.

Vertex Pharmaceuticals (VRTX) fell 4.1% to $486.44 after BofA Securities cut its price target to $667, citing lower Trikafta revenue expectations. Citi maintained a Buy rating with a $585 target. Analysts remain bullish, but concerns over newer products and reliance on cystic fibrosis treatments weighed on the stock.

Biotech stocks are rebounding due to record pharmaceutical M&A deals, with 37 acquisitions worth at least $1B each in 2026, totaling $216B. Key deals include Vertex (VRTX) acquiring Crinetics (CRNX) for $10B. Institutional investors are bullish, but retail sentiment is low. The Direxion Biotech Bull 3x Shares (LABU) fund has gained 52.5% YTD, despite its index being down last week.

Truist Securities previewed Q3 2026 earnings for eight biotech companies, highlighting Insmed (INSM), BridgeBio (BBIO), and Neurocrine (NBIX) for potential volatility. Insmed's Brinsupri forecast was reduced due to lower prescription trends. BridgeBio's revenue surged 202% to $713M with 94% gross margins. The FDA accepted BridgeBio's NDA for infigratinib, with analysts maintaining Buy ratings and price targets.

BofA Securities reduced its price target for Vertex Pharmaceuticals (VRTX) to $667 from $672, maintaining a Buy rating. The company expects Q3 revenue of $2.42B for Trikafta, down 3% QoQ, and raised its 2026 revenue guidance to $13.1B-$13.2B. Vertex is a top pick for 2026, according to BofA, which is bullish on its cystic fibrosis franchise. Other analysts have also raised price targets following positive trial data for its kidney disease treatment, inaxaplin.

Vertex Pharmaceuticals reported interim data suggesting ALYFTREK may restore pancreatic function in 2–5 year-olds with cystic fibrosis, potentially allowing discontinuation of pancreatic enzyme replacement therapy. The use of ALYFTREK in this age group is still investigational, according to the company.